Phase 2b Trial Protocol for Preventing Lung Disease in Preterm Infants
Randomised al.Phase 2b trial of rhIGF-1/rhIGFBP-3 (OHB-607) for bronchopulmonary dysplasia prevention in preterm neonates: study protocol.
Background
Bronchopulmonary dysplasia (BPD) is a severe chronic lung disease affecting preterm neonates, leading to significant morbidity and mortality. Despite advances in neonatal care, BPD remains a major challenge with no specific preventative pharmacological treatments available. This study protocol addresses the critical knowledge gap regarding effective therapeutic strategies to prevent BPD in this vulnerable population.
Study Design
Population
Preterm neonates at risk of bronchopulmonary dysplasia (BPD).
Intervention
Not specified in this protocol digest.
Comparator
Not specified in this protocol digest.
Outcome
Prevention of bronchopulmonary dysplasia (BPD).
